Back to Search
Start Over
Dietary restriction but not rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS.
- Source :
-
Neurobiology of aging [Neurobiol Aging] 2012 Aug; Vol. 33 (8), pp. 1829-32. Date of Electronic Publication: 2011 Jul 18. - Publication Year :
- 2012
-
Abstract
- Dietary restriction (DR) and rapamycin (Rapa) have been shown to increase the lifespan of a variety of organisms leading to the speculation that these interventions increase lifespan through related mechanisms. However, both these interventions have a detrimental effect in the G93A mutant mouse model of amyotrophic lateral sclerosis (ALS). Our previous work indicated that different ALS SOD1 mutant mouse models differ in disease pathogenesis; therefore in this study we measured the effect of DR and Rapa in a second ALS mutant mouse model (the H46R/H48Q mutant). Interestingly, in mice expressing this mutant SOD1 protein, DR significantly delays disease onset and extends lifespan, while Rapa has no effect. These findings suggest that: (1) the effect of DR in ALS is not mediated through pathways common with Rapa, (2) the deleterious effect of DR and Rapa in the G93A ALS mouse model may not be universal to disease caused by all SOD1 mutations, and (3) the results reinforce our previous conclusions that the pathogenic mechanisms in G93A and H46R/H48Q mice are distinct.<br /> (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Subjects :
- Amyotrophic Lateral Sclerosis diagnosis
Animals
Humans
Immunosuppressive Agents administration & dosage
Mice
Mice, Transgenic
Survival Analysis
Survival Rate
Treatment Outcome
Amyotrophic Lateral Sclerosis physiopathology
Amyotrophic Lateral Sclerosis therapy
Caloric Restriction methods
Disease Models, Animal
Sirolimus administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1558-1497
- Volume :
- 33
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Neurobiology of aging
- Publication Type :
- Academic Journal
- Accession number :
- 21763036
- Full Text :
- https://doi.org/10.1016/j.neurobiolaging.2011.06.002